Back to Search Start Over

Impact of conditioning regimen on peripheral blood hematopoietic cell transplant.

Authors :
Burns M
Singh AK
Hoefer CC
Zhang Y
Wallace PK
Chen GL
Platek A
Winslow TB
Iovoli AJ
Choi C
Ross M
McCarthy PL
Hahn T
Source :
World journal of clinical oncology [World J Clin Oncol] 2019 Feb 24; Vol. 10 (2), pp. 86-97.
Publication Year :
2019

Abstract

Aim: To investigate infused hematopoietic cell doses and their interaction with conditioning regimen intensity +/- total body irradiation (TBI) on outcomes after peripheral blood hematopoietic cell transplant (PBHCT).<br />Methods: Our retrospective cohort included 247 patients receiving a first, T-replete, human leukocyte antigen-matched allogeneic PBHCT and treated between 2001 and 2012. Correlations were calculated using the Pearson product-moment correlation coefficient. Overall survival and progression free survival curves were generated using the Kaplan-Meier method and compared using the log-rank test.<br />Results: Neutrophil engraftment was significantly faster after reduced intensity TBI based conditioning [reduced intensity conditioning (RIC) + TBI] and > 4 × 10 <superscript>6</superscript> CD34+ cells/kg infused. A higher total nucleated cell dose led to a higher incidence of grade II-IV acute graft-versus-host disease in the myeloablative + TBI regimen group ( P = 0.03), but no significant difference in grade III-IV graft-versus-host disease. A higher total nucleated cell dose was also associated with increased incidence of moderate/severe chronic graft-versus-host disease, regardless of conditioning regimen. Overall and progression-free survival were significantly better in patients with a RIC + TBI regimen and total nucleated cell dose > 8 × 10 <superscript>8</superscript> /kg (3 years, overall survival: 70% vs 38%, P = 0.02, 3 years, progression free survival: 64% vs 38%, P = 0.02).<br />Conclusion: TBI and conditioning intensity may alter the relationship between infused cell doses and outcomes after PBHCT. Immune cell subsets may predict improved survival after unmanipulated PBHCT.<br />Competing Interests: Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.

Details

Language :
English
ISSN :
2218-4333
Volume :
10
Issue :
2
Database :
MEDLINE
Journal :
World journal of clinical oncology
Publication Type :
Academic Journal
Accession number :
30815375
Full Text :
https://doi.org/10.5306/wjco.v10.i2.86